Accéder au contenu
Merck
Toutes les photos(1)

Documents

Y0001434

Montelukast sodium

European Pharmacopoeia (EP) Reference Standard

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C35H35ClNO3S·Na
Numéro CAS:
151767-02-1
Poids moléculaire :
608.17
Code UNSPSC :
41116107
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

montelukast

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

InChI

1S/C35H36ClNO3S.Na/c1-34(2,40)30-9-4-3-7-25(30)13-17-32(41-23-35(18-19-35)22-33(38)39)27-8-5-6-24(20-27)10-15-29-16-12-26-11-14-28(36)21-31(26)37-29;/h3-12,14-16,20-21,32,40H,13,17-19,22-23H2,1-2H3,(H,38,39);/q;+1/p-1/b15-10+;/t32-;/m1./s1

Clé InChI

LBFBRXGCXUHRJY-HKHDRNBDSA-M

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Montelukast sodium EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

Y0001433

Montelukast racemate, European Pharmacopoeia (EP) Reference Standard

Y0001435

Montelukast for peak identification, European Pharmacopoeia (EP) Reference Standard

Y0001436

Montelukast dicyclohexylamine, European Pharmacopoeia (EP) Reference Standard

1446859

Montelukast sodium, United States Pharmacopeia (USP) Reference Standard

1446848

Montelukast racemate, United States Pharmacopeia (USP) Reference Standard

1446815

Montelukast dicyclohexylamine, United States Pharmacopeia (USP) Reference Standard

1446837

Montelukast for peak identification, United States Pharmacopeia (USP) Reference Standard

BP1147

Montelukast dicyclohexylamine, British Pharmacopoeia (BP) Reference Standard

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Timothy S Chang et al.
The Journal of allergy and clinical immunology, 133(2), 363-369 (2013-10-22)
Childhood asthma clusters, or subclasses, have been developed by computational methods without evaluation of clinical utility. To replicate and determine whether childhood asthma clusters previously identified computationally in the Severe Asthma Research Program (SARP) are associated with treatment responses in
Chenghua Zhou et al.
Anesthesia and analgesia, 118(5), 1090-1096 (2014-04-02)
Cysteinyl leukotrienes and their receptors have been shown to be involved in the generation of neuropathic pain. We performed this study to determine the antagonistic effect of montelukast, a cysteinyl leukotrienes receptor antagonist, on neuropathic pain and its underlying mechanism.
Nathan Rabinovitch et al.
The Journal of allergy and clinical immunology, 133(2), 350-356 (2013-10-03)
Predictors of improvement in asthma control and lung function to step 3 therapy in children with persistent asthma have not been identified despite reported heterogeneity in responsiveness. We sought to evaluate potential predictors of asthma control and lung function responsiveness
Genyo Ikeda et al.
American journal of respiratory cell and molecular biology, 50(1), 18-29 (2013-08-14)
The incidence of overlapping bronchial asthma and chronic obstructive pulmonary disease has increased in recent years. Cysteinyl leukotrienes (CysLTs) play an important role in asthma, and the type 1 CysLT receptor (CysLT1R) is expressed by many inflammatory cells. We evaluated
Yves Pacheco et al.
The Journal of asthma : official journal of the Association for the Care of Asthma, 51(1), 1-17 (2013-07-10)
Rhinitis and other specific triggers or co-morbidities (tobacco exposure, excess weight, aspirin sensitivity or heredity factors) are frequently associated with uncontrolled asthma. Asthma associated with these exacerbating factors appears to be related to an increase in leukotriene-mediated inflammation. We reviewed
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique